From the Divisions of Nephrology (C.L.) and Cardiology (G.M.), San Jorge
General Hospital, Huesca; the Department of Clinical Chemistry, University
Clinic (N.V., J.F., M.J.G., I.M.), and Vascular Pathophysiology Unit, School
of Medicine (J.D.), University of Navarra, Pamplona; and the Department of
Medicine, School of Medicine, University of Zaragoza (J.D.), Spain.
Correspondence to Javier Díez, MD, PhD, Unidad de Fisiopatología Vascular, Facultad de Medicina, C/Irunlarrea s/n, 31080 Pamplona, Spain.
Background—This study was designed
to investigate whether collagen type I degradation is altered in
patients with essential hypertension and whether this alteration could
be related to disturbances in the serum matrix
metalloproteinase pathway of collagen degradation. A second aim of the
study was to assess whether some relation exists between serum markers
of collagen type I degradation and left ventricular
hypertrophy in hypertensive patients.
Methods and Results—We measured serum concentrations of
carboxy-terminal telopeptide of collagen type I (CITP) as a marker of
extracellular collagen type I degradation, of total matrix
metalloproteinase-1 (MMP-1), or collagenase, of total
tissue inhibitor of metalloproteinases 1 (TIMP-1), and of
MMP-1/TIMP-1 complex in 37 patients with never-treated essential
hypertension and in 23 normotensive control subjects. Serum
concentrations of free MMP-1 and free TIMP-1 were calculated by
subtracting the values of MMP-1/TIMP-1 complex from the values of total
MMP-1 and total TIMP-1, respectively. Measurements were repeated in 26
hypertensive patients after 1 year of treatment with the ACE
inhibitor lisinopril. Baseline free MMP-1 was
decreased (P<0.001) and baseline free TIMP-1 was
increased (P<0.001) in hypertensives compared with
normotensives. No significant differences were observed in the baseline
values of CITP between the 2 groups of subjects. Hypertensive patients
with baseline left ventricular hypertrophy
exhibited lower values of free MMP-1 (P<0.01) and CITP
(P<0.05) and higher (P<0.001) values of
free TIMP-1 than hypertensive patients without baseline left
ventricular hypertrophy. Treated patients
attained an increase (P<0.001) in free MMP-1 and a
decrease (P<0.05) in free TIMP-1. In addition, serum
CITP was increased (P<0.05) in treated hypertensives
compared with normotensive subjects.
Conclusions—These findings suggest that systemic extracellular
degradation of collagen type I is depressed in patients with essential
hypertension and can be normalized by treatment with
lisinopril. A depressed degradation of collagen type I may
facilitate organ fibrosis in hypertensive patients, namely, in those
with left ventricular hypertrophy.
© 1998 American Heart Association, Inc.
Clinical Investigation and Reports
Abnormalities of the Extracellular Degradation of Collagen Type I in Essential Hypertension
Key Words: collagen • hypertension • metalloproteinases • peptides • remodeling
This article has been cited by other articles:
 |
|
 |
|
  D. Kelly, S. Q. Khan, M. Thompson, G. Cockerill, L. L. Ng, N. Samani, and I. B. Squire Plasma tissue inhibitor of metalloproteinase-1 and matrix metalloproteinase-9: novel indicators of left ventricular remodelling and prognosis after acute myocardial infarction Eur. Heart J., July 8, 2008; (2008) ehn315v1. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Garcia-Bolao, B. Lopez, A. Macias, J. J. Gavira, P. Azcarate, and J. Diez Impact of collagen type I turnover on the long-term response to cardiac resynchronization therapy Eur. Heart J., April 1, 2008; 29(7): 898 - 906. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M M. Lindsay and F. G Dunn Biochemical evidence of myocardial fibrosis in veteran endurance athletes Br. J. Sports Med., July 1, 2007; 41(7): 447 - 452. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Flamant, S. Placier, C. Dubroca, B. Esposito, I. Lopes, C. Chatziantoniou, A. Tedgui, J.-C. Dussaule, and S. Lehoux Role of Matrix Metalloproteinases in Early Hypertensive Vascular Remodeling Hypertension, July 1, 2007; 50(1): 212 - 218. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Gonzalez, A. M. Briones, B. Somoza, C. J. Daly, E. Vila, B. Starcher, J. C. McGrath, M. C. Gonzalez, and S. M. Arribas Postnatal alterations in elastic fiber organization precede resistance artery narrowing in SHR Am J Physiol Heart Circ Physiol, August 1, 2006; 291(2): H804 - H812. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Lopez, A. Gonzalez, R. Querejeta, M. Larman, and J. Diez Alterations in the Pattern of Collagen Deposition May Contribute to the Deterioration of Systolic Function in Hypertensive Patients With Heart Failure J. Am. Coll. Cardiol., July 4, 2006; 48(1): 89 - 96. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. H. Ahmed, L. L. Clark, W. R. Pennington, C. S. Webb, D. D. Bonnema, A. H. Leonardi, C. D. McClure, F. G. Spinale, and M. R. Zile Matrix Metalloproteinases/Tissue Inhibitors of Metalloproteinases: Relationship Between Changes in Proteolytic Determinants of Matrix Composition and Structural, Functional, and Clinical Manifestations of Hypertensive Heart Disease Circulation, May 2, 2006; 113(17): 2089 - 2096. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Lubos, R. Schnabel, H. J. Rupprecht, C. Bickel, C. M. Messow, S. Prigge, F. Cambien, L. Tiret, T. Munzel, and S. Blankenberg Prognostic value of tissue inhibitor of metalloproteinase-1 for cardiovascular death among patients with cardiovascular disease: results from the AtheroGene study Eur. Heart J., January 2, 2006; 27(2): 150 - 156. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Cuspidi, M. Ciulla, and A. Zanchetti Hypertensive myocardial fibrosis Nephrol. Dial. Transplant., January 1, 2006; 21(1): 20 - 23. [Full Text] [PDF]
|
|
|
|
|
|
H. Izawa, T. Murohara, K. Nagata, S. Isobe, H. Asano, T. Amano, S. Ichihara, T. Kato, S. Ohshima, Y. Murase, et al. Mineralocorticoid Receptor Antagonism Ameliorates Left Ventricular Diastolic Dysfunction and Myocardial Fibrosis in Mildly Symptomatic Patients With Idiopathic Dilated Cardiomyopathy: A Pilot Study Circulation, November 8, 2005; 112(19): 2940 - 2945. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. M. Deschamps, K. A. Apple, A. H. Leonardi, J. E. McLean, W. M. Yarbrough, R. E. Stroud, L. L. Clark, J. A. Sample, and F. G. Spinale Myocardial Interstitial Matrix Metalloproteinase Activity Is Altered by Mechanical Changes in LV Load: Interaction With the Angiotensin Type 1 Receptor Circ. Res., May 27, 2005; 96(10): 1110 - 1118. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Rizzoni, E. Porteri, C. De Ciuceis, I. Sleiman, L. Rodella, R. Rezzani, S. Paiardi, R. Bianchi, G. Ruggeri, G. E.M. Boari, et al. Effect of Treatment With Candesartan or Enalapril on Subcutaneous Small Artery Structure in Hypertensive Patients With Noninsulin-Dependent Diabetes Mellitus Hypertension, April 1, 2005; 45(4): 659 - 665. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Yasmin, S. Wallace, C. M. McEniery, Z. Dakham, P. Pusalkar, K. Maki-Petaja, M. J. Ashby, J. R. Cockcroft, and I. B. Wilkinson Matrix Metalloproteinase-9 (MMP-9), MMP-2, and Serum Elastase Activity Are Associated With Systolic Hypertension and Arterial Stiffness Arterioscler. Thromb. Vasc. Biol., February 1, 2005; 25(2): 372 - 378. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Sundstrom, J. C. Evans, E. J. Benjamin, D. Levy, M. G. Larson, D. B. Sawyer, D. A. Siwik, W. S. Colucci, P. W.F. Wilson, and R. S. Vasan Relations of plasma total TIMP-1 levels to cardiovascular risk factors and echocardiographic measures: the Framingham heart study Eur. Heart J., September 1, 2004; 25(17): 1509 - 1516. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. M. Ciulla, R. Paliotti, A. Esposito, J. Diez, B. Lopez, B. Dahlof, M. G. Nicholls, R. D. Smith, L. Gilles, F. Magrini, et al. Different Effects of Antihypertensive Therapies Based on Losartan or Atenolol on Ultrasound and Biochemical Markers of Myocardial Fibrosis: Results of a Randomized Trial Circulation, August 3, 2004; 110(5): 552 - 557. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. L. Schiffrin and R. M. Touyz From bedside to bench to bedside: role of renin-angiotensin-aldosterone system in remodeling of resistance arteries in hypertension Am J Physiol Heart Circ Physiol, August 1, 2004; 287(2): H435 - H446. [Full Text] [PDF]
|
|
|
|
|
|
B. Lopez, R. Querejeta, A. Gonzalez, E. Sanchez, M. Larman, and J. Diez Effects of loop diuretics on myocardial fibrosis and collagen type I turnover in chronic heart failure J. Am. Coll. Cardiol., June 2, 2004; 43(11): 2028 - 2035. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A Rossi, M Cicoira, G Golia, L Zanolla, L Franceschini, P Marino, M Graziani, and P Zardini Amino-terminal propeptide of type III procollagen is associated with restrictive mitral filling pattern in patients with dilated cardiomyopathy: a possible link between diastolic dysfunction and prognosis Heart, June 1, 2004; 90(6): 650 - 654. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Cox, U. A. Hawkins, B. D. Hoit, and S. C. Tyagi Attenuation of Oxidative Stress and Remodeling by Cardiac Inhibitor of Metalloproteinase Protein Transfer Circulation, May 4, 2004; 109(17): 2123 - 2128. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. E. Chapman and F. G. Spinale Extracellular protease activation and unraveling of the myocardial interstitium: critical steps toward clinical applications Am J Physiol Heart Circ Physiol, January 1, 2004; 286(1): H1 - H10. [Full Text] [PDF]
|
|
|
|
|
|
R. Lombardi, S. Betocchi, M. A. Losi, C. G. Tocchetti, M. Aversa, M. Miranda, G. D'Alessandro, A. Cacace;, Q. Ciampi, and M. Chiariello Myocardial Collagen Turnover in Hypertrophic Cardiomyopathy Circulation, September 23, 2003; 108(12): 1455 - 1460. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Marin, V. Roldan, V. Climent, A. Garcia, P. Marco, and G. Y.H. Lip Is Thrombogenesis in Atrial Fibrillation Related to Matrix Metalloproteinase-1 and Its Inhibitor, TIMP-1? Stroke, May 1, 2003; 34(5): 1181 - 1186. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Tsuruda, G. Boerrigter, B. K. Huntley, J. A. Noser, A. Cataliotti, L. C. Costello-Boerrigter, H. H. Chen, and J. C. Burnett Jr Brain Natriuretic Peptide Is Produced in Cardiac Fibroblasts and Induces Matrix Metalloproteinases Circ. Res., December 13, 2002; 91(12): 1127 - 1134. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. M. Grandi, D. Imperiale, R. Santillo, E. Barlocco, A. Bertolini, L. Guasti, and A. Venco Aldosterone Antagonist Improves Diastolic Function in Essential Hypertension Hypertension, November 1, 2002; 40(5): 647 - 652. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. M. Maceira, J. Barba, O. Beloqui, and J. Diez Ultrasonic Backscatter and Diastolic Function in Hypertensive Patients Hypertension, September 1, 2002; 40(3): 239 - 243. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. M. Lindsay, P. Maxwell, and F. G. Dunn TIMP-1: A Marker of Left Ventricular Diastolic Dysfunction and Fibrosis in Hypertension Hypertension, August 1, 2002; 40(2): 136 - 141. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Diez, R. Querejeta, B. Lopez, A. Gonzalez, M. Larman, and J. L. Martinez Ubago Losartan-Dependent Regression of Myocardial Fibrosis Is Associated With Reduction of Left Ventricular Chamber Stiffness in Hypertensive Patients Circulation, May 28, 2002; 105(21): 2512 - 2517. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. T. Weber Aldosterone in Congestive Heart Failure N. Engl. J. Med., December 6, 2001; 345(23): 1689 - 1697. [Full Text] [PDF]
|
|
|
|
|
|
B. Lopez, A. Gonzalez, N. Varo, C. Laviades, R. Querejeta, and J. Diez Biochemical Assessment of Myocardial Fibrosis in Hypertensive Heart Disease Hypertension, November 1, 2001; 38(5): 1222 - 1226. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-B. Michel Contrasting Outcomes of Atheroma Evolution: Intimal Accumulation Versus Medial Destruction Arterioscler. Thromb. Vasc. Biol., September 1, 2001; 21(9): 1389 - 1392. [Full Text] [PDF]
|
|
|
|
|
|
H. D. Intengan and E. L. Schiffrin Vascular Remodeling in Hypertension: Roles of Apoptosis, Inflammation, and Fibrosis Hypertension, September 1, 2001; 38(3): 581 - 587. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Lopez, R. Querejeta, N. Varo, A. Gonzalez, M. Larman, J. L. Martinez Ubago, and J. Diez Usefulness of Serum Carboxy-Terminal Propeptide of Procollagen Type I in Assessment of the Cardioreparative Ability of Antihypertensive Treatment in Hypertensive Patients Circulation, July 17, 2001; 104(3): 286 - 291. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N.-E. Rhaleb, H. Peng, X.-P. Yang, Y.-H. Liu, D. Mehta, E. Ezan, and O. A. Carretero Long-Term Effect of N-Acetyl-Seryl-Aspartyl-Lysyl-Proline on Left Ventricular Collagen Deposition in Rats With 2-Kidney, 1-Clip Hypertension Circulation, June 26, 2001; 103(25): 3136 - 3141. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Rodrigo, M. Lopez-Hoyos, R. Escallada, G. Fernandez-Fresnedo, J. C. Ruiz, C. Pinera, J. G. Cotorruelo, J. A. Zubimendi, A. L. M. de Francisco, and M. Arias Circulating levels of matrix metalloproteinases MMP-3 and MMP-2 in renal transplant recipients with chronic transplant nephropathy Nephrol. Dial. Transplant., December 1, 2000; 15(12): 2041 - 2045. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G.Y.H Lip, D.C Felmeden, F.L Li-Saw-Hee, and D.G Beevers Hypertensive heart disease. A complex syndrome or a hypertensive 'cardiomyopathy'? Eur. Heart J., October 2, 2000; 21(20): 1653 - 1665. [PDF]
|
|
|
|
|
|
C. Laviades, N. Varo, and J. Diez Transforming Growth Factor {beta} in Hypertensives With Cardiorenal Damage Hypertension, October 1, 2000; 36(4): 517 - 522. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. D. Intengan and E. L. Schiffrin Structure and Mechanical Properties of Resistance Arteries in Hypertension : Role of Adhesion Molecules and Extracellular Matrix Determinants Hypertension, September 1, 2000; 36(3): 312 - 318. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Schwartzkopff, M. Brehm, M. Mundhenke, and B. E. Strauer Repair of Coronary Arterioles After Treatment With Perindopril in Hypertensive Heart Disease Hypertension, August 1, 2000; 36(2): 220 - 225. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Gonzalez, V. Fontaine, M. E. Pueyo, N. Laquay, D. Messika-Zeitoun, M. Philippe, J.-F. Arnal, M.-P. Jacob, and J.-B. Michel Molecular Plasticity of Vascular Wall During NG-Nitro-L-Arginine Methyl Ester-Induced Hypertension : Modulation of Proinflammatory Signals Hypertension, July 1, 2000; 36(1): 103 - 109. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. G Brilla Regression of myocardial fibrosis in hypertensive heart disease: diverse effects of various antihypertensive drugs Cardiovasc Res, May 1, 2000; 46(2): 324 - 331. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Querejeta, N. Varo, B. Lopez, M. Larman, E. Artinano, J. C. Etayo, J. L. M. Ubago, M. Gutierrez-Stampa, J. I. Emparanza, M. J. Gil, et al. Serum Carboxy-Terminal Propeptide of Procollagen Type I Is a Marker of Myocardial Fibrosis in Hypertensive Heart Disease Circulation, April 11, 2000; 101(14): 1729 - 1735. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Feng, J.-H. Yang, H. Huang, S. P. Kennedy, T. G. Turi, J. F. Thompson, P. Libby, and R. T. Lee Transcriptional Profile of Mechanically Induced Genes in Human Vascular Smooth Muscle Cells Circ. Res., December 3, 1999; 85(12): 1118 - 1123. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. T. Weber Monitoring Vascular Sclerosis in Hypertension : A New Window of Opportunity Circulation, August 11, 1998; 98(6): 498 - 500. [Full Text] [PDF]
|
|